We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Traditional vaccine development remains a critically slow, resource-intensive, and costly process, often unable to respond adequately to rapidly emerging infectious diseases. Recent advances in Artificial Intelligence (AI), including Machine Learning (ML) and Deep Learning (DL), have begun to transform key stages of vaccinology, supporting rational antigen discovery, precise epitope prediction, and immunogenicity modeling. Simultaneously, the emergence of powerful RNA foundation models—most notably RiNALMo—has enabled highly accurate, sequence-level inference of RNA structure and critical regulatory features from massive non-coding RNA corpora. RiNALMo, the largest RNA language model to date with 650 million parameters pre-trained on 36 million curated non-coding RNAs, implicitly captures complex biological signals such as secondary structure, splice-site features, and translational regulatory motifs. This review synthesizes current progress in AI-driven vaccinology and RNA language modeling, emphasizing the strategic integration of antigen-level AI tools with structure-aware RNA models for next-generation mRNA vaccine design. While these approaches offer unprecedented speed, precision, and scalability, key challenges—including data heterogeneity, achieving model interpretability, and establishing regulatory frameworks—must be addressed to fully realize this promising convergence that may redefine next-generation vaccine development.
Vaccines have played a decisive role in reducing global mortality. (Plotkin et al.1 Rappuoli et al.2). Despite this success, conventional vaccine development is characterized by lengthy cycles of antigen identification, experimental epitope validation, and iterative wet-lab testing. (Delany et al.3). This methodical approach often spans years, with high attrition rates, sometimes exceeding 80% from preclinical stages to market approval, (Pronker et al4; Gouglas et al5), hindering timely deployment during outbreaks.
Artificial Intelligence (AI) has emerged as a transformative solution to many of these bottlenecks. (Topol et al6, Jiang et al7 ). AI techniques enhance every stage, from antigen selection and epitope mapping to adjuvant discovery and immunogenicity prediction. (Vamathevan et al. [8]; Akbar et al. [9]; Ong et al. [10]). These advancements leverage biological language models originally developed for Natural Language Processing (NLP) but repurposed to decode protein and nucleic-acid sequences. (Rives et al. [11]). More recently, RNA foundation models—such as RNA-FM, Uni-RNA, and RiNALMo—have extended these capabilities by learning RNA "grammar" directly from vast sequence data, (Chen et al. [12]; Xiong et al. [13]; Li et al. [14]), which is especially significant for the design and optimization of mRNA vaccines.
METHODS
A structured literature search was performed using PubMed, Scopus, Web of Science, and Google Scholar, covering the period from January 2010 to May 2024. (Page et al. [15]). Search terms included “artificial intelligence,” “machine learning,” “vaccine design,” “epitope prediction,” “antigen selection,” “RNA language model,” “RiNALMo,” and “mRNA vaccine optimization”. Eligible studies included peer-reviewed research articles, technical reports, and reviews focusing on AI applications in vaccinology or the development of protein/RNA language models. Conference abstracts, commentaries without methodological detail, and non-English articles were excluded. Relevant articles were screened and synthesized qualitatively. Themes included model architectures, dataset characteristics, performance outcomes, and translational relevance. Findings were integrated to describe the convergence of vaccinology and RNA modeling. (Kitchenham et al. [16]; Snyder et al. [17]).
AI-Driven Applications in Vaccine Development
AI techniques support multiple stages of modern vaccine design and optimization, providing improved speed and accuracy over conventional methods.
Table 1. Representative AI and RNA Language Models Relevant to Vaccine Research
|
Sr. No |
Model |
Type |
Dataset |
Key Features |
Applications |
|
1. |
Alpha Fold |
Protein structure model |
Millions of protein sequences |
Deep neural architecture |
Predicting 3D protein structure (Jumper et al.[22]) |
|
2. |
ESM-1b |
Protein language model |
250M sequences |
Transformer, masked LM |
Secondary structure, evolutionary signals (Rives et al.11) |
|
3. |
RiNALMo |
RNA foundation model |
36M ncRNAs |
650M parameters, RoPE, SwiGLU, Flash Attention-2 |
RNA structure prediction, translation modeling (Li et al.14) |
|
4. |
RNA-FM |
RNA language model |
Large ncRNA corpus |
Self-supervised training |
RNA family classification (Chen et al.12) |
|
5. |
SpliceBERT |
Specialized RNA model |
pre-mRNA sequences |
BERT-based encoder |
Splice-site prediction (Xiong et al13) |
RNA Language Models and Their Functional Capabilities (Significantly Expanded)
RNA language models provide critical insights into RNA structure and regulation, enabling more precise design of mRNA vaccine constructs.
Architecture of RiNALMo: RiNALMo (RiboNucleic Acid Language Model) is the largest RNA language model to date. It is a 650-million-parameter Transformer model trained on 36 million carefully curated non-coding RNAs (ncRNAs) using masked language modeling (MLM). (Li et al.14 Townshend et al.24) Its advanced architecture incorporates modern techniques like Rotary Positional Embedding (RoPE), SwiGLU activation function, and FlashAttention-2, which enable efficient long-range feature learning and high scalability.
Structural and Functional Prediction: RiNALMo extracts hidden knowledge and captures underlying structural information implicitly embedded within RNA sequences at the single-nucleotide level. It achieves state-of-the-art performance in secondary structure prediction, demonstrating strong generalization to RNA families not seen during training. Furthermore, it accurately predicts splice-site features, mean ribosome loading (MRL), translation efficiency (TE), and expression levels (EL) derived from 5′ UTR sequences. (Townshend et al. [24]; Hie et al. [25]).
Advantages Over Classical RNA Tools: By learning RNA structural “grammar” directly from sequence, RiNALMo’s generalization capabilities overcome the inability of other deep learning methods to perform well on unseen RNA families. Analysis of RiNALMo’s sequence embeddings shows that it can cluster RNAs by family with clean boundaries, suggesting it has learned properties related to structure and function beyond the primary sequence. This capability makes it particularly valuable for designing diverse or synthetic RNAs relevant to vaccine design. (Townshend et al. [24]; Hie et al. [25]).
Current Challenges: Limitations include the under-representation of viral and synthetic RNA in current training corpora, which affects its robustness for vaccine-specific applications. Like all deep models, there is limited interpretability of its internal representations, which necessitates reliance on systematic experimental validation to confirm predicted RNA behaviors. Hie et al 25
Convergence of AI Vaccinology and RNA Foundation Models (Enhanced)
The integration of antigen-level AI tools and structure-aware RNA foundation models provides a unified computational pipeline crucial for accelerating mRNA vaccine development.
Rationale for Integration: mRNA vaccine efficacy is a function of both the engineered antigen (the target) and the structural/regulatory properties of the mRNA molecule itself (the vehicle). AI vaccinology identifies high-priority antigenic targets, such as B-cell and T-cell epitopes. Concurrently, RNA foundation models predict and optimize key mRNA characteristics, including sequence stability, folding energy, mean ribosome loading, and translation efficiency, ensuring robust expression in vivo.
A Combined Computational Pipeline: The most efficient pipeline combines these synergistic strengths:
FUTURE DIRECTIONS
Addressing the limitations of current systems will pave the way for next-generation platforms:
CONCLUSION
AI-driven vaccine design and RNA language modeling represent a transformative and essential convergence in modern biotechnology. While general AI accelerates the front-end stages of antigen discovery and epitope prediction, highly specialized RNA foundation models like RiNALMo enable the precise, structure-aware engineering of the mRNA construct itself. Together, this synergy supports the rapid development of next-generation vaccines with intrinsically improved expression, stability, and immunogenicity. Continued, dedicated advances in data quality, model interpretability, and the establishment of robust, responsive regulatory frameworks will be critical for the safe and effective implementation of these revolutionary AI-enabled vaccine platforms.
REFERENCES
Sonale S, Revanth R, Integrating Artificial Intelligence and RNA Foundation Models for Accelerated Vaccine Development, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 8, 1391-1397. https://doi.org/10.5281/zenodo.21840378
10.5281/zenodo.21840378